Drug-resistant infections pose a grave threat, with deaths potentially doubling to eight million annually by 2050. A thin pipeline of new drugs, down from 92 to 60 in the last five years, is alarming. GlaxoSmithKline leads with 30 projects, but Pfizer has fallen behind. Despite this, three new antibiotics have been approved, and seven more are in late-stage trials, offering hope. The urgency for better treatments is high, especially in low- and middle-income countries where resistance is rising rapidly.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/b09b15baed37f791
